NuVasive (NUVA) Getting Somewhat Favorable Press Coverage, Report Shows

News stories about NuVasive (NASDAQ:NUVA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 48.2658392193769 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of NUVA stock traded down $0.12 during trading hours on Friday, hitting $70.19. 347,300 shares of the company’s stock traded hands, compared to its average volume of 760,567. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.89 and a beta of 0.58. NuVasive has a 12-month low of $44.62 and a 12-month high of $71.15.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.58. The company had revenue of $281.56 million during the quarter, compared to the consensus estimate of $276.05 million. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. analysts forecast that NuVasive will post 2.39 earnings per share for the current year.

Several analysts have commented on NUVA shares. Needham & Company LLC lowered their price objective on shares of NuVasive from $69.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, August 1st. BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Saturday, May 26th. ValuEngine upgraded shares of NuVasive from a “strong sell” rating to a “sell” rating in a report on Monday, July 30th. Zacks Investment Research lowered shares of NuVasive from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. Finally, Cantor Fitzgerald initiated coverage on shares of NuVasive in a report on Thursday, May 31st. They set a “neutral” rating and a $54.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.06.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Story: Trading Strategy Examples and Plans

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.

Leave a Reply